C34H36MgN6O6S2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: C34H36MgN6O6S2
• 化学式: C17H19MgN3O3S
• 分子量: 369.7
• InChiKey: MQEUGMWHWPYFDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.52
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  96.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole potassium salt 、 溶剂黄146 、 甲醇 、 magnesium;dichloride;hexahydrate 在 甲醇 、 水 作用下， 以 水 为溶剂， 反应 11.75h， 生成 C34H36MgN6O6S2
  参考文献：
  名称：

  Process for producing sulphoxide compounds

  摘要：

  本文揭示了一种制备公式（I）的亚硫酰化合物的过程，该过程通过在手性过渡金属配合物的存在下，在不使用有机溶剂和碱的情况下，使用有效量的氧化剂不对称氧化公式（II）的原手性硫醚。

  公开号：

  US08173818B2

文献信息

• Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties
  申请人：Gant G. Thomas

  公开号：US20070082929A1

  公开（公告）日：2007-04-12

  Chemical syntheses and medical uses of novel inhibitors of the gastric H + , K + -ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.

  描述了用于治疗和/或管理十二指肠溃疡、胃灼热、酸反流、其他由胃酸分泌介导的疾病以及牛皮癣的新型胃H+、K+-ATP酶抑制剂的化学合成和医学用途。
• Process for solvent removal from omeprazole salts
  申请人：LEK Pharmaceuticals d.d.

  公开号：EP1947099A1

  公开（公告）日：2008-07-23

  The present invention relates to a process for removing an organic solvent from a salt of omeprazole, in particular a magnesium salt of omeprazole, a composition comprising a salt of omeprazole, in particular a magnesium salt of omeprazole obtainable by such a process, and pharmaceutical compositions comprising said composition or a salt of omeprazole, in particular a magnesium salt of omeprazole, in particular where omeprazole is S-omeprazole..

  本发明涉及一种从奥美拉唑的盐中去除有机溶剂的方法，特别是从奥美拉唑的镁盐中去除有机溶剂的方法，包括一种奥美拉唑的盐，特别是通过这种方法获得的奥美拉唑的镁盐，以及包含所述组合物或奥美拉唑的盐的药物组合物，特别是奥美拉唑为S-奥美拉唑。
• Novel process for the preparation of esomeprazole and salts thereof
  申请人：Wang Fan

  公开号：US20070287839A1

  公开（公告）日：2007-12-13

  A novel process for the preparation of omeprazole and its enantiomers, such as esomeprazole, as well as the preparation of related 2-(2-pyridinylmethyl-sulphinyl)-1H-benzimidazoles, including pantoprazole, lansoprazole and rabeprazole, as recemates or single enantiomers, and their alkali or alkaline salts has been developed. The novel process involves the surprising discovery that protection of the free-base benzimidazole sulfoxide (e.g. omeprazole or esomeprazole), by reaction with an alkyl, aryl or aralkyl chloroformate following oxidation of the corresponding sulfide, eliminates the need for its direct isolation. Subsequent removal of the protecting group with a solution of alkali or alkaline earth alkoxide in a C1-C4 alcohol directly provides the corresponding salt. By eliminating the need to handle the free-base benzimidazole sulfoxide, this advantageous procedure provides increased chemical yields over processes described in the art.

  一种新型制备奥美拉唑及其对映体（如左旋奥美拉唑）以及相关的2-(2-吡啶甲基-亚砜基)-1H-苯并咪唑类化合物（包括泮托拉唑、兰索拉唑和雷贝拉唑）的方法已经开发出来。这种新型方法涉及到一个惊人的发现，即通过与烷基、芳基或芳基氯甲酸酯反应保护游离基苯并咪唑亚砜氧化物（例如奥美拉唑或左旋奥美拉唑），随后通过对应硫醚的氧化消除了对其直接分离的需求。随后，通过使用C1-C4醇中碱或碱土金属烷氧化物溶液去除保护基，直接得到相应的盐。通过消除处理游离基苯并咪唑亚砜氧化物的需求，这种优势的程序提供了比文献中描述的工艺更高的化学产率。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Metal coordinated compositions
  申请人：Piccariello Thomas

  公开号：US20060141054A1

  公开（公告）日：2006-06-29

  A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.

  本发明揭示了一种生物活性基团和金属配位复合物。该复合物使得生物活性基团具有改进的性能，包括效能、稳定性、吸收性、定向传递性以及它们的组合。